Mary Binsu Abraham

Mary Binsu Abraham

Auto-generated profile, based on publicly available information

Mary Binsu Abraham

Department of Endocrinology and Diabetes Perth Children's Hospital Perth Western Australia Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
MAMary B. Abraham
Mary B. Abraham
TJTimothy W. Jones
Timothy W. Jones
DNDiana Naranjo
Diana Naranjo
BKBeate Karges
Beate Karges
AOAbiola Oduwole
Abiola Oduwole
DMDavid M. Maahs
David M. Maahs

20 December 2022 in Pediatric Diabetes
Verified
Journal Article
Open access
MAMary B. Abraham
Mary B. Abraham
BKBeate Karges
Beate Karges
KDKlemen Dovc
Klemen Dovc
DNDiana Naranjo
Diana Naranjo
AAAna Maria Arbelaez
Ana Maria Arbelaez
FMFarid H. Mahmud
Farid H. Mahmud

30 June 2019 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
MBM.‐A. Burckhardt
M.‐A. Burckhardt
LFL. Fried
L. Fried
KBK. Bebbington
K. Bebbington
MHM. Hancock
M. Hancock
JNJ. A. Nicholas
J. A. Nicholas
TJT. W. Jones
T. W. Jones

25 January 2017 in International Journal of Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
MAMary B. Abraham
Mary B. Abraham
DLDong Li
Dong Li
DTDave Tang
Dave Tang
SOSusan M. O’cOnnell
Susan M. O’cOnnell
FMFiona McKenzie
Fiona McKenzie
CCCatherine S. Choong
Catherine S. Choong
Hypoparathyroidism in children is a heterogeneous group with diverse genetic etiologies. To aid clinicians in the investigation and management of children with hypoparathyroidism, we describe the phenotype of a 6-year-old child with hypoparathyroidism and short stature diagnosed with Kenny-Caffey syndrome (KCS) Type 2 and the subsequent response to growth hormone (GH) treatment. The proband presented in the neonatal period with hypocalcemic seizures secondary to hypoparathyroidism. Her phenotype included small hands and feet, hypoplastic and dystrophic nails, hypoplastic mid-face and macrocrania. Postnatal growth was delayed but neurodevelopment was normal. A skeletal survey at 2 years of age was suggestive of KCS Type 2 and genetic testing revealed a novel de novo heterozygous mutation c.1622C > A (p.Ser541Tyr) in FAM111A. At 3 years and 2 months, her height was 80cms (SDS −3.86). She had normal overnight GH levels. GH therapy was commenced at a dose of 4.9 mg/m2/week for her short stature and low height velocity of 5cms/year. At the end of the first and second years of GH treatment, height velocity was 6.5cms/year and 7.2cms/year, respectively with maximal dose of 7.24 mg/m2/week. This case highlights the phenotype and the limited response to GH in a child with genetically proven KCS type 2. Long-term registries monitoring growth outcomes following GH therapy in patients with rare genetic conditions may help guide clinical decisions regarding the use and doses of GH in these conditions.

29 June 2021 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
MBMarie-Anne Burckhardt
Marie-Anne Burckhardt
MAMary Binsu Abraham
Mary Binsu Abraham
JDJulie Dart
Julie Dart
GSGrant J. Smith
Grant J. Smith
NPNirubasini Paramalingam
Nirubasini Paramalingam
TJTimothy W. Jones
Timothy W. Jones
Objective: This study evaluated the efficacy of using a hybrid closed loop (HCL) system in restoring hypoglycemia awareness in individuals with impaired awareness of hypoglycemia (IAH). Research Design and Methods: Participants with IAH (Gold score ≥4) were recruited into a randomized crossover pilot study. They participated in two 8-week periods using a HCL system (Medtronic 670G™) (intervention) and standard insulin pump therapy (control). Hyperinsulinemic hypoglycemic clamp studies were undertaken at baseline and at the end of each study period for the evaluation of the counter-regulatory hormonal and symptomatic responses to hypoglycemia. Results: Seventeen participants (mean age [standard deviation] 35.8 years [11.2 years]) were included in the study. Peak epinephrine levels (median, interquartile range [IQR]) in response to hypoglycemia were similar postintervention and control periods; 234.7 pmol/L (109.2; 938.9) versus 188.3 pmol/L (133.7; 402.9), P = 0.233. However, both peak adrenergic and neuroglycopenic symptom scores were higher after intervention; 5.0 (4.5; 9.0) versus 4.0 (4.0; 5.5), P = 0.009, and 8.5 (6.0; 15.0) versus 6.5 (6.0; 7.0) P = 0.014, respectively. Self-reported hypoglycemia awareness improved: median (IQR) Gold score was 4.0 (3.0; 5.5) versus 5.5 (4.5; 6.0); intervention versus control, P = 0.033. Time spent <3.9 and <3.0 mmol/L was lower in the intervention group than in control, P = 0.002. Other patient-reported outcomes (hypoglycemia fear and diabetes treatment satisfaction) did not change. Conclusions: A short-term use of a HCL system failed to demonstrate an improvement in counter-regulatory hormonal responses. However, higher hypoglycemia symptom scores during controlled hypoglycemia, better self-reported hypoglycemia awareness, and less time spent in hypoglycemia suggest the potential benefits of a HCL system in people with IAH. Trial Registration: anzctr.org.au Identifier: ACTRN12616000909426.

1 September 2016 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
MAMary B. Abraham
Mary B. Abraham
RDRaymond Davey
Raymond Davey
MOMichael J. O'GRady
Michael J. O'GRady
TLTrang T. Ly
Trang T. Ly
NPNirubasini Paramalingam
Nirubasini Paramalingam
EDElizabeth Davis
Elizabeth Davis
Background: Sensor-augmented pump therapy (SAPT) with a predictive algorithm to suspend insulin delivery has the potential to reduce hypoglycemia, a known obstacle in improving physical activity in patients with type 1 diabetes. The predictive low glucose management (PLGM) system employs a predictive algorithm that suspends basal insulin when hypoglycemia is predicted. The aim of this study was to determine the efficacy of this algorithm in the prevention of exercise-induced hypoglycemia under in-clinic conditions. Methods: This was a randomized, controlled cross-over study in which 25 participants performed 2 consecutive sessions of 30 min of moderate-intensity exercise while on basal continuous subcutaneous insulin infusion on 2 study days: a control day with SAPT alone and an intervention day with SAPT and PLGM. The predictive algorithm suspended basal insulin when sensor glucose was predicted to be below the preset hypoglycemic threshold in 30 min. We tested preset hypoglycemic thresholds of 70 and 80 mg/dL. The primary outcome was the requirement for hypoglycemia treatment (symptomatic hypoglycemia with plasma glucose <63 mg/dL or plasma glucose <50 mg/dL) and was compared in both control and intervention arms. Results: Results were analyzed in 19 participants. In the intervention arm with both thresholds, only 6 participants (32%) required treatment for hypoglycemia compared with 17 participants (89%) in the control arm ( P = 0.003). In participants with a 2-h pump suspension on intervention days, the plasma glucose was 84 ± 12 and 99 ± 24 mg/dL at thresholds of 70 and 80 mg/dL, respectively. Conclusions: SAPT with PLGM reduced the need for hypoglycemia treatment after moderate-intensity exercise in an in-clinic setting.